Syndax Pharmaceuticals【SNDX】銘柄情報

Syndax Pharmaceuticals Inc (SNDX) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

21.0451

( 6.23% )

買値

21.05

売値

21.25

出来高

4,567,245

19.92 日の範囲 21.36

8.585 52 週間の範囲 25.59

時価総額

1.865B

前日終値

19.81

始値

20.09

時刻

21.25

最終取引時間

財務取引量

US$ 94,005,434

VWAP

20.5825

平均取引量 (3 か月)

US$ 1,740,112

発行済株式数

88,610,027

配当利回り

PER

-6.81

1 株当たり利益 (EPS)

-2.79

歳入

217.17M

純利益

-243.25M

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a co... Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

syndax.com

本社

New York, United States

設立

2026

Syndax Pharmaceuticals Inc is listed in the Healthcare sector of the ナスダック市場 with ticker SNDX. The last closing price for Syndax Pharmaceuticals was US$19.81. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of US$ 8.585 to US$ 25.59.

Syndax Pharmaceuticals currently has 88,610,027 shares in issue. The market capitalisation of Syndax Pharmaceuticals is US$1.86 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.81.

全体の流れ

ブルリッシュ

ネットプレミアム

63k

Calls / Puts

100.00%

買い / 売り

100.00%

OTM / ITM

100.00%

Sweeps比率

0.00%

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar...

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	1.8351	9.55283706403	19.21	21.32	18.94	1646844	19.7009022	CS
4	1.2951	6.55746835443	19.75	21.32	16.66	2097967	18.44974792	CS
12	-4.0349	-16.0881180223	25.08	25.531	16.66	1726087	20.19197975	CS
26	-0.6849	-3.15186378279	21.73	25.59	16.66	1526089	21.04812774	CS
52	12.0951	135.140782123	8.95	25.59	8.585	1997067	17.13916245	CS
156	-0.1949	-0.917608286252	21.24	25.59	8.58	1697605	16.61504714	CS
260	1.9051	9.95350052247	19.14	29.86	8.58	1289594	17.44063167	CS